Cyclophosphamide-sensitive and cyclophosphamide-resistant suppressor cells in the immune response to alloantigens
- PMID: 313108
Cyclophosphamide-sensitive and cyclophosphamide-resistant suppressor cells in the immune response to alloantigens
Abstract
We have demonstrated that within a given system Cy may alter the immune response in different ways. It may augment the response by inactivating CSS cells or induce immunosuppression by activating CRS. Furthermore, our studies provide a means of analyzing the mechanism of suppression, that is, delineating the target cell for suppression, the properties and life span of the suppressed cells, and the nature of the cell interactions involved. Furthermore, with the available information on the immunosuppressive activity of Cy, clinical studies may be best monitored in transplantation immunology and tumor chemotherapy. It is possible that the induction of CRS cells, which are antigen-nonspecific and non-H-2-restricted, may be useful for inducing specific immunosuppression to alleviate GVH reactions. These studies are currently in progress.
Similar articles
-
Modulation of T-dependent cell-mediated immune responses by antigen-reactive cell opsonization and active suppression.Transplant Proc. 1978 Mar;10(1):31-5. Transplant Proc. 1978. PMID: 76350
-
Antigen-antibody complexes generate Lyt 1 inducers of suppressor cells.J Immunol. 1980 Jul;125(1):63-7. J Immunol. 1980. PMID: 6966663
-
The influence of cyclophosphamide on antibody formation in the mouse.Ann Immunol (Paris). 1975 Apr;126(3):267-79. Ann Immunol (Paris). 1975. PMID: 1101799
-
Modulation of immune responses by suppressor T cells.Fed Proc. 1978 Aug;37(10):2361-64. Fed Proc. 1978. PMID: 79503 Review.
-
Tumor induced immunosuppression.Surg Gynecol Obstet. 1983 Feb;156(2):233-40. Surg Gynecol Obstet. 1983. PMID: 6186039 Review. No abstract available.
Cited by
-
Regulatory T cells in radiotherapeutic responses.Front Oncol. 2012 Aug 17;2:90. doi: 10.3389/fonc.2012.00090. eCollection 2012. Front Oncol. 2012. PMID: 22912933 Free PMC article.
-
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.Br J Cancer. 1996 Oct;74(8):1292-6. doi: 10.1038/bjc.1996.532. Br J Cancer. 1996. PMID: 8883420 Free PMC article. Clinical Trial.
-
After chemotherapy, functional humoral response capacity is restored before complete restoration of lymphoid compartments.Clin Exp Immunol. 2003 Jan;131(1):8-16. doi: 10.1046/j.1365-2249.2003.02044.x. Clin Exp Immunol. 2003. PMID: 12519380 Free PMC article.